AMP-activated protein kinase and O-GlcNAcylation : a new paradigm to protect the failing heart
(2022)
Files
FinalThesis_JustineDontaine.pdf
Closed Access - Adobe PDF
- 239.41 MB
Details
- Authors
- Supervisors
- Abstract
- Cardiovascular diseases are the leading cause of death in the world. Among them, heart failure is a complex syndrome characterized by the inability of the heart to sustain proper cardiac output to meet metabolic demands of organs. The deleterious outcome of this progressive disease is associated with chronic cardiac hypertrophy and a general increase in protein O-GlcNAcylation, an emerging post-translational modification. Our team has previously highlighted that the reduction of O-GlcNAcylation following AMPK activation prevents the development of cardiac hypertrophy. In the present work, we show that AMPK-mediated inhibition of O-GlcNAcylation not only reverses cardiomyocyte hypertrophy in vitro, but also improves cardiac function in an in vivo model of cardiac hypertrophy. In addition, proteomic analysis allowed us to identify numerous O-GlcNAcylated proteins, rainsing novel potential therapeutic strategies for the treatment of heart failure.
- Affiliations
Citations
Dontaine, J. (2022). AMP-activated protein kinase and O-GlcNAcylation : a new paradigm to protect the failing heart. https://hdl.handle.net/2078.5/102443